Sep 21, 2016 Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder
Sep 12, 2016 Cerecor Enters Into a $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
Sep 6, 2016 Cerecor Announces Last Patient Enrolled in Phase 2 Clinical Trial with CERC-501 for Smoking Cessation
Sep 1, 2016 Cerecor to Present at 23rd Annual NewsMakers in the Biotech Industry Conference in New York City, September 9, 2016
Aug 22, 2016 Cerecor to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
Jul 25, 2016 Cerecor Announces Research Grant from the Department of Defense to Study CERC-501 in Animal Models for Co-Morbid Post-Traumatic Stress Disorder and Alcohol Use Disorder
Jul 20, 2016 Cerecor Announces $1.0 Million Research & Development Grant from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health
